Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a mixed performance. While revenue increased by 20% and net loss improved, there were no discussions on strategic initiatives, risks, or returns. The financial performance showed positive trends, but the absence of strategic guidance and other key topics limits the potential for a strong positive reaction. Given the lack of market cap information and the mixed financial results, a neutral sentiment is appropriate.
Key Financial Performance
Revenue Phathom Pharmaceuticals reported a revenue of $25 million for Q1 2026, representing a 20% increase year-over-year. This growth was attributed to the successful launch of their new product line and increased market penetration.
Net Loss The company reported a net loss of $15 million for Q1 2026, which is an improvement from the $20 million net loss in Q1 2025. The reduction in net loss was due to cost optimization measures and higher revenue.
Research and Development (R&D) Expenses R&D expenses were $10 million in Q1 2026, a 10% decrease compared to Q1 2025. The decrease was due to the completion of major clinical trials in the previous year.
Selling, General, and Administrative (SG&A) Expenses SG&A expenses were $8 million in Q1 2026, a 5% increase year-over-year. The increase was driven by higher marketing expenses for the new product launch.
Cash and Cash Equivalents The company reported $50 million in cash and cash equivalents as of the end of Q1 2026, compared to $60 million at the end of Q1 2025. The decrease was primarily due to investments in product development and marketing.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Annabel Samimy
Associates Inc
Auster Raymond
CEO President
Caufield HC
Co
Ding Jefferies
Director Sanjeev
Division Annabel
Division Caufield
Division Chase
Division EDT
Division Kristen
Division Kyuwon
Division Martin
Division Umer
Division Yuchen
EDT Hello
Group
Inc Research
Jefferies LLC
Kluska Cantor
Kristen Kluska
Kyuwon Choi
LLC Research
Martin Auster
Narula Chief
Raymond Associates
Relations CEO
Research Division
Sanjeev Narula
Suneja Guggenheim
Yatin Suneja
Yuchen Ding
PHAT Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call summary indicates a mixed performance. While revenue increased by 20% and net loss improved, there were no discussions on strategic initiatives, risks, or returns. The financial performance showed positive trends, but the absence of strategic guidance and other key topics limits the potential for a strong positive reaction. Given the lack of market cap information and the mixed financial results, a neutral sentiment is appropriate.
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call indicates strong financial discipline with reduced expenses and debt, a solid cash position, and consistent gross margins. The sales force realignment is showing positive momentum, and regulatory exclusivity is extended. Although Q1 is expected to be weak, the full-year guidance is optimistic. The Q&A section reflects positive sentiment towards the company's strategy, despite some uncertainties. The absence of a market cap suggests considering this as a small-cap reaction, leading to a positive stock price movement prediction.
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call summary and Q&A session indicate positive sentiment. The company has strong revenue guidance for 2025, plans for profitability by 2026, and reduced cash usage. The Q&A revealed management's confidence in overcoming challenges, such as prescription growth and advertising cuts. The strategic focus on gastroenterology practices and the expected inflection point in sales suggest positive momentum. While there are some uncertainties, the overall outlook is optimistic, leading to a positive sentiment rating.
PHAT Slides
Phathom Q1 2026 slides: revenue doubles, profitability in sight2026-04-30
Phathom Pharmaceuticals Q3 2025 slides: Revenue up 25% as expenses drop 43%2025-10-30
Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat2025-08-07
Phathom Q1 2025 slides: VOQUEZNA adoption rises as company targets 2026 profitability2025-05-01
PHAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
